News
RDY
13.60
+0.37%
0.05
Hims & Hers launches generics for Novo’s semaglutide in Canada
Seeking Alpha · 3d ago
Dr. Reddy’s Files Form 6-K and Publishes FY26 Earnings Call Transcript
TipRanks · 5d ago
Dr. Reddy’s Schedules Global Investor Meetings for Late May–Early June 2026
TipRanks · 6d ago
Weekly Report: what happened at RDY last week (0511-0515)?
Weekly Report · 6d ago
Reported Saturday, Dr. Reddy's Breaks Ground As First Generic Semaglutide Injection Launcher In Canada, Expanding Global GLP-1 Therapy Access
Benzinga · 6d ago
Dr. Reddy’s launches generic Semaglutide injection in Canada
TipRanks · 6d ago
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
Benzinga · 05/16 19:17
DR. REDDY'S LABORATORIES LAUNCHES ITS GENERIC SEMAGLUTIDE INJECTION IN CANADA
Reuters · 05/16 07:18
Dr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada Nod
TipRanks · 05/15 20:17
BUZZ-Pfizer's India unit drops on quarterly profit fall
Reuters · 05/13 06:57
BUZZ-Street View - India's Dr Reddy's facing pricing pressure and competition
Reuters · 05/13 04:36
Dr. Reddy’s Earnings Call: Growth vs. Margin Pain
TipRanks · 05/13 00:15
Dr. Reddy’s Unveils FY 2026 Results, Dividend and Board, Auditor Changes
TipRanks · 05/12 22:45
Dr. Reddy’s Files Q4 FY26 Audited Results Presentation with Exchanges
TipRanks · 05/12 22:44
Dr. Reddy's proposes final dividend of INR 8 per share for FY2025-26
PUBT · 05/12 21:02
Dr. Reddy’s posts audio of March-quarter 2026 earnings call for investors
TipRanks · 05/12 19:17
Dr. Reddy’s to become first to sell Ozempic generics in Canada
Seeking Alpha · 05/12 18:46
Dr. Reddy's GAAP EPS of $0.03, revenue of $801M misses by $54.01M
Seeking Alpha · 05/12 15:51
Dr. Reddy’s Revamps Board, Auditors and Senior Leadership in May 12 Governance Push
TipRanks · 05/12 14:40
Dr. Reddy’s names Deloitte Haskins & Sells LLP as statutory auditor for five years
PUBT · 05/12 14:03
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.